Crescent Biopharma (CBIO) set to announce earnings on Thursday. October 29, 2026 Key points. * Crescent Biopharma is expected to report quarterly results before the market opens on Thursday, November 5, with analysts projecting a loss of $0.6739 per share and revenue of $0.36 million. * CBIO shares opened at $13.50, well below the company's 12-month high of $27.41. Analysts maintain an average "Buy" rating and a consensus price target of $33.00. * Company executives recently sold shares under pre-arranged Rule 10b5-1 plans to cover tax obligations; insiders sold 16,726 shares worth $285,501 over the past 90 days. * Five stocks we like better than Crescent Biopharma. Crescent Biopharma (NASDAQ:CBIO - Get Free Report) is projected to issue its results before the market opens on Thursday, November 5th. Analysts expect Crescent Biopharma to post earnings of ($0.6739) per share and revenue of $0.36 million for the quarter. Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) EPS for the quarter, meeting analysts' consensus estimates of ($0.74). On average, analysts expect Crescent Biopharma to post ($2.93) EPS for the current fiscal year and ($3.17) EPS for the next fiscal year. Crescent Biopharma price performance. NASDAQ CBIO opened at $13.50 on Thursday. Crescent Biopharma has a 12 month low of $8.72 and a 12 month high of $27.41. The firm has a market capitalization of $501.39 million, a PE ratio of -2.01 and a beta of 1.27. The company's 50 day simple moving average is $15.74 and its 200 day simple moving average is $15.80. Analyst upgrades and downgrades. Several brokerages have commented on CBIO. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target on shares of Crescent Biopharma in a research report on Monday, October 19th. TD Cowen raised Crescent Biopharma to a "strong-buy" rating in a research report on Monday, August 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Crescent Biopharma in a research note on Friday, August 7th. Wedbush restated an "outperform" rating and set a $27.00 price target on shares of Crescent Biopharma in a report on Monday, September 14th. Finally, UBS Group reaffirmed a "buy" rating and set a $36.00 price objective on shares of Crescent Biopharma in a report on Monday, October 19th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Crescent Biopharma has an average rating of "Buy" and an average price target of $33.00. Discover more MarketBeat All Access MarketBeat Research Tools Insider activity. In other news, COO Jonathan McNeill sold 3,839 shares of Crescent Biopharma stock in a transaction on Friday, September 18th. The stock was sold at an average price of $16.71, for a total value of $64,149.69. Following the completion of the sale, the chief operating officer directly owned 134,588 shares of the company's stock, valued at approximately $2,248,965.48. This trade represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Joshua T. Brumm sold 7,837 shares of Crescent Biopharma stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.71, for a total transaction of $130,956.27. Following the sale, the chief executive officer owned 271,765 shares of the company's stock, valued at approximately $4,541,193.15. This represents a 2.80% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 16,726 shares of company stock worth $285,501. 24.84% of the stock is owned by insiders. About Crescent Biopharma. Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Crescent Biopharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list. While Crescent Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely. Continue following MarketBeat

Crescent Biopharma, Inc. announces clinical pipeline momentum. Published on 10/15/2026 at 04:15 pm EDT S&P Capital IQ Crescent Biopharma, Inc. announced clinical pipeline momentum, including enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1/2 ASCEND trial, as well as the initiation of additional antibody-drug conjugate (ADC) combination studies with CR-001. Crescent has completed dose escalation in the global Phase 1/2 ASCEND trial of CR-001, its investigational PD-1 x VEGF bispecific, developed in collaboration with Paragon Labs, with patients enrolled across several tumor types at clinical sites in the United States, Europe and South Korea. The Company plans to report initial monotherapy data from ASCEND in the first quarter of 2027, including preliminary antitumor response as measured by overall response rate (ORR) from a first-line NSCLC cohort of up to 12 patients. The Company plans to report initial monotherapy data from ASCEND in the first quarter of 2027, including safety, tolerability, pharmacokinetic and pharmacodynamic data from more than 125 treatment-naïve and previously-treated patients across multiple solid tumor types. Enrollment has commenced in the standard of care chemotherapy combination expansion cohorts of ASCEND. Hundreds of participants are expected to enroll in this part of the study with various tumor types and chemotherapy regimens being evaluated, including first-line (1L) NSCLC: CR-001 + paclitaxel and carboplatin (squamous) or pemetrexed and carboplatin (non-squamous). Hundreds of participants are expected to enroll in this part of the study with various tumor types and chemotherapy regimens being evaluated, including 1L mismatch repair proficient (pMMR) /microsatellite stable (MSS) colorectal cancer (CRC): CR-001 + mFOLFOX6. Hundreds of participants are expected to enroll in this part of the study with various tumor types and chemotherapy regimens being evaluated, including third-line (3L) CRC: CR-001 + trifluridine and tipiracil. Hundreds of participants are expected to enroll in this part of the study with various tumor types and chemotherapy regimens being evaluated, including 1L biliary tract cancer: CR-001 + gemcitabine and cisplatin. Hundreds of participants are expected to enroll in this part of the study with various tumor types and chemotherapy regimens being evaluated, including 1L pMMR endometrial cancer: CR-001 + carboplatin and paclitaxel. Hundreds of participants are expected to enroll in this part of the study with various tumor types and chemotherapy regimens being evaluated, including 1L programmed cell death ligand 1 (PD-L1)-expressing gastric/gastroesophageal junction (GEJ) cancer: CR-001 + capecitabine and oxaliplatin. Hundreds of participants are expected to enroll in this part of the study with various tumor types and chemotherapy regimens being evaluated, including second-line (2L) PD-L1-expressing gastric/GEJ cancer: CR-001 + paclitaxel. Crescent plans to report initial data from the chemotherapy combination cohorts in mid-2027 (second quarter/third quarter). Data from these cohorts, along with monotherapy data from ASCEND, will inform future clinical development for CR-001. Trial in progress posters on the ASCEND study design will be presented during the European Society for Medical Oncology (ESMO) 2026 Congress being held October 23-27, 2026 in Madrid, Spain and at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting being held November 4-8, 2026 in Phoenix, Arizona. Both Kelun-Biotech and Crescent have rights to independently develop CR-001 in combinations, including with their respective ADC pipelines. Kelun-Biotech is conducting multiple trials in China evaluating CR-001 in combination with sacituzumab tirumotecan (sac-TMT), its TROP2-directed ADC, and additional ADC combination studies are planned. A Phase 2 trial of CR-001 (SKB118) and sac-TMT in participants with locally advanced or metastatic NSCLC is ongoing with initial data expected in mid-2027 (second quarter/third quarter). A Phase 2 trial of sac-TMT in combination with CR-001 (SKB118) is now enrolling participants with advanced solid tumors. A Phase 2 trial of sac-TMT in combination with CR-001 (SKB118) is initiating in epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-squamous NSCLC who have failed EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. A Phase 1/2 trial of CR-001(SKB118) in combination with CR-003 (also known as SKB105), an integrin-beta 6 (ITGB6)-directed ADC, is expected to commence in the first half of 2027. Earlier this month, CR-002, Crescent?s topoisomerase inhibitor ADC targeting PD-L1, internally developed in collaboration with Paragon Labs, received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration. Crescent is on track to initiate the global Phase 1/2 APOLLO trial this quarter in patients with advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma (HNSCC), and various gastrointestinal and gynecological tumors. Initial data are expected in the second half of 2027. A Phase 1/2 trial of CR-003 (SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in China is ongoing and proof-of-concept data are expected in the first quarter of 2027. Crescent plans to leverage data generated in China to support the global clinical development of CR-003 (SKB105). (C) S&P Capital IQ - GlobeNewswire - 2026